Primary hyperoxaluria type 1 (PH1) Program in Pharmaceutical Benefits Scheme (PBS) 012-25090506

This document outlines details of PBS-subsidised lumasiran for patients with primary hyperoxaluria type 1 (PH1).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Primary hyperoxaluria type 1 (PH1) quick reference

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial PB389 form	Written Electronic S85: lumasiran	No	OPA	Must be treated by: a nephrologist with experience in the management of hyperoxaluria a paediatrician with experience in the management of hyperoxaluria an authorised prescriber in consultation with one of the above specialty types	Yes - delayed assessment due to DPMQ (cost)
Grandfather PB391 form	Written Electronic S85: lumasiran	No	OPA	Must be treated by: a nephrologist with experience in the management of hyperoxaluria a paediatrician with experience in the management of hyperoxaluria an authorised prescriber in consultation with one of the above specialty types	Yes - delayed assessment due to DPMQ (cost)
Continuing PB390 form	Written Electronic S85: lumasiran	No	OPA	Must be treated by: a nephrologist with experience in the management of hyperoxaluria a paediatrician with experience in the management of hyperoxaluria an authorised prescriber in consultation with one of the above specialty types	Yes